NCT03818061 (ATHENA) is a Phase 2 clinical trial of Atezolizumab in Head and Neck Neoplasms, sponsored by Centre Leon Berard.

Who is sponsoring NCT03818061?

NCT03818061 is sponsored by Centre Leon Berard.

What drugs are being tested in NCT03818061?

Interventions in NCT03818061: Atezolizumab, Bevacizumab.

What condition does NCT03818061 study?

NCT03818061 studies Head and Neck Neoplasms.

Is NCT03818061 still recruiting?

NCT03818061 is currently status unknown. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT03818061: ATHENA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Status unknown Phase 2 Last updated 28 September 2023

What this trial tests

Phase 2 trial testing Atezolizumab in Head and Neck Neoplasms in 33 participants. Status unknown.

Timeline

26 March 2019

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Centre Leon Berard
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	26 March 2019
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	7 locations across France

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →

Sponsor

Centre Leon Berard — full company profile →

Who can join

18 and older, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proof-of-concept study aims to assess the clinical and biological effects of Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma of the head and neck (HNSCC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S, Shah PA, Johnson FM. · · 2022 · cited 47× · PMID 35887235 · DOI 10.3390/ijms23147889
A review on the advances and challenges of immunotherapy for head and neck cancer.
Cheng G, Dong H, Yang C, Liu Y, et al · · 2021 · cited 46× · PMID 34332576 · DOI 10.1186/s12935-021-02024-5
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.
Ortiz-Cuaran S, Bouaoud J, Karabajakian A, Fayette J, et al · · 2021 · cited 45× · PMID 33718169 · DOI 10.3389/fonc.2021.614332
TGFβ<sup>+</sup> small extracellular vesicles from head and neck squamous cell carcinoma cells reprogram macrophages towards a pro-angiogenic phenotype.
Ludwig N, Yerneni SS, Azambuja JH, Pietrowska M, et al · · 2022 · cited 44× · PMID 36537293 · DOI 10.1002/jev2.12294
An update on angiogenesis targeting in head and neck squamous cell carcinoma.
Micaily I, Johnson J, Argiris A. · · 2020 · cited 42× · PMID 32280512 · DOI 10.1186/s41199-020-00051-9
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer.
Economopoulou P, Kotsantis I, Psyrri A. · · 2020 · cited 39× · PMID 33203092 · DOI 10.3390/cancers12113377
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H, Zhao Q, Zhang Y, Zhang Q, et al · · 2021 · cited 33× · PMID 34305889 · DOI 10.3389/fimmu.2021.652054
Current Insights and Progress in the Clinical Management of Head and Neck Cancer.
Amaral MN, Faísca P, Ferreira HA, Gaspar MM, et al · · 2022 · cited 32× · PMID 36551565 · DOI 10.3390/cancers14246079

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Head and Neck Neoplasms

Currently open trials in the same condition.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting

Other Centre Leon Berard trials

Trials by the same sponsor.

NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
NCT07515274 — Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer · NA · not yet recruiting
NCT07243483 — Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My · NA · recruiting
NCT07334990 — Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Canc · NA · not yet recruiting
NCT07414719 — Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03818061 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Leon Berard
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03818061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing